rss
Ann Rheum Dis 72:381-389 doi:10.1136/annrheumdis-2012-201411
  • Clinical and epidemiological research

Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial

Table 1

Summary of demographics at baseline; randomised patients

Placebo+MTX Golimumab 2 mg/kg+MTX Total
Patients randomised 197 395 592
Age (years)
 Mean±SD 51.4±11.26 51.9±12.55 51.8±12.13
 Median 52.0 53.0 52.0
 Range (19, 78) (18, 83) (18, 83)
Sex, n (%)
 Male 40 (20.3) 69 (17.5) 109 (18.4)
 Female 157 (79.7) 326 (82.5) 483 (81.6)
Disease duration (years)
 Mean±SD 7.0±7.24 6.9±7.00 6.9±7.08
 Median (IQR) 4.8 (1.9, 9.6) 4.6 (1.8, 9.6) 4.7 (1.9, 9.6)
Number of swollen joints (0–66)
 Mean±SD 14.8±8.54 15.0±8.23 14.9±8.33
 Median (IQR) 12.0 (8.0, 19.0) 12.0 (9.0, 19.0) 12.0 (9.0, 19.0)
Number of tender joints (0–68)
 Mean±SD 25.9±14.13 26.4±13.93 26.3±13.99
 Median (IQR) 22.0 (14.0, 36.0) 24.0 (15.0, 35.0) 23.0 (15.0, 35.0)
C-reactive protein (normal≤1.0 mg/dl)
 Mean±SD 2.2±1.88 2.8±2.86 2.6±2.59
 Median (IQR) 1.7 (0.9, 3.0) 2.0 (1.0, 3.4) 1.9 (0.9, 3.3)
DAS28-CRP
 Mean±SD 5.9±0.93 6.0±0.82 5.9±0.86
 Median (IQR) 6.0 (5.2, 6.6) 5.9 (5.3, 6.5) 5.9 (5.3, 6.5)
CDAI (0–76)
 Mean±SD 38.4±12.40 38.5±11.60 38.4±11.86
 Median (IQR) 38.0 (28.8, 47.1) 37.0 (29.8, 45.7) 37.3 (29.7, 45.9)
SDAI (0–86)
 Mean±SD 40.6±12.85 41.3±12.29 41.1±12.47
 Median (IQR) 40.0 (30.5, 50.2) 39.8 (31.9, 49.3) 39.8 (31.0, 49.6)
HAQ disability index (0–3)
 Mean±SD 1.6±0.62 1.6±0.67 1.6±0.65
 Median (IQR) 1.6 (1.3, 2.0) 1.6 (1.1, 2.0) 1.6 (1.1, 2.0)
  • CDAI, clinical disease activity index; CRP, C-reactive protein, DAS28, disease activity score employing 28 joints; HAQ, health assessment questionnaire; MTX, methotrexate; SDAI, simplified disease activity index.

Free sample This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article